Psoriasis VulgarisNCT05279638
ATG5 as a Serum Marker of Autophagy in Psoriatic Patient
An observational study of Psoriasis Vulgaris and Autophagy, run by Sohag University at 1 site in Egypt.
Trial summary
it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Psoriasis Vulgaris, Autophagy
- What is being tested?
- serum ATG5
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Feb 2022to 1 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Patients with psoriasis vulgaris and healthy participatins
Who may be able to join
- Psoriasis vulgaris of both sex, age 18-55 years
Who cannot join
- Patients with other types of psoriasis ii. Pregnant or lactating women iii. patients with hepatic or renal diseases iv. patients receive any systemic treatment in last 3 months
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of ATG5 as Aserum Marker of Autophgy in Psoriasis Vulgaris Patients
it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.
- Conditions
- Psoriasis Vulgaris, Autophagy
- Being tested
- serum ATG5
- Keywords
- serum marker, ATG5
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
serum ATG5Diagnostic test
Also called human autophgy protien 5 ELISA kit
This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
| Study group | Role | What they receive |
|---|---|---|
| psoriasis vulgaris patients | psoriasis vulgaris patients , both sex , 18,55 years old Receives: Diagnostic Test: serum ATG5 | |
| healthy participants | Not described Receives: Diagnostic Test: serum ATG5 |
What is being measured
The primary outcome is the main question the study is designed to answer.
serum level of ATG5 in psoriatic patients
evaluation of serum ATG5 in psoriasis vulgaris patients by ELISA
Measured: Within 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2022
- Study start1 Feb 2022
- Primary completion1 Feb 2023 (estimated)
- Study completion1 Jan 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psoriasis VulgarisStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ayatallah Hamdy Abdelrahim, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05279638
- Sponsor's protocol ID
- Soh-Med-22-02-03
- Status last verified
- Mar 2022
- First submitted
- 23 Feb 2022
- Last updated
- 15 Mar 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of ATG5 as Aserum Marker of Autophgy in Psoriasis Vulgaris Patients
- ClinicalTrials.gov ID
- NCT05279638
- Acronym / sponsor ID
- Soh-Med-22-02-03
- Conditions
- Psoriasis Vulgaris, Autophagy
- Keywords
- serum marker, ATG5
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Feb 2022 (actual)
- Primary completion
- 1 Feb 2023 (estimated)
- Study completion
- 1 Jan 2024 (estimated)
- First posted
- 15 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| psoriasis vulgaris patients | – | Diagnostic Test: serum ATG5psoriasis vulgaris patients , both sex , 18,55 years old |
| healthy participants | – | Diagnostic Test: serum ATG5 |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Patients with psoriasis vulgaris and healthy participatins
Key inclusion criteria (1 listed)
- Psoriasis vulgaris of both sex, age 18-55 years
Key exclusion criteria (1 listed)
- Patients with other types of psoriasis ii. Pregnant or lactating women iii. patients with hepatic or renal diseases iv. patients receive any systemic treatment in last 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| serum ATG5Also: human autophgy protien 5 ELISA kitThis kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid | Diagnostic test | healthy participants, psoriasis vulgaris patients |
Primary outcome
serum level of ATG5 in psoriatic patients
Time frame: Within 6 months
evaluation of serum ATG5 in psoriasis vulgaris patients by ELISA
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Mar 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Psoriasis Vulgaris
Active, not recruitingPhase 4
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
Psoriasis Vulgaris, Psoriasis
RecruitingObservational study
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Acne, Atopic Dermatitis
RecruitingPhase 4
Topical Diacerein in Psoriasis Vulgaris
Psoriasis Vulgaris
Not yet recruiting
Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)
Psoriasis, Psoriasis; Plaque
RecruitingPhase 1
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants
Psoriasis Vulgaris
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psoriasis Vulgaris and Autophagy, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ayatallah Hamdi Abdelrahmim (01005482447, ayatallah_hamdy_post@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
serum level of ATG5 in psoriatic patients (time frame: Within 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2022.